Product
IFX-1
2 clinical trials
2 indications
Indication
COVID-19 pneumoniaIndication
Squamous Cell Carcinoma of SkinClinical trial
A Pragmatic Adaptive Randomized, Controlled Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 PneumoniaStatus: Completed, Estimated PCD: 2021-10-31
Clinical trial
Open Label, Multicenter Phase II Study of the C5a Antibody IFX-1 Alone or IFX-1 + Pembrolizumab in Patients With PD-1 or PD-L1 Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)Status: Active (not recruiting), Estimated PCD: 2024-06-30